ABBOTT LABORATORIES
In the published model solve dated 2026-Q2, anchored at $112.48, ABBOTT LABORATORIES (ABT) is priced for +13.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Diabetes Care is the largest single line in the business at about 18% of revenue and also the fastest-moving one: continuous glucose monitoring sales ⟦totaled $7.6 billion in 2025 and $6.4 billion in 2024⟧. • The company has just changed its own risk profile. Abbott closed the roughly $21 billion purchase of Exact Sciences in March 2026 [Source: Abbott press release, March 20, 2026], having arranged a ⟦364-day senior unsecured bridge term loan facility for an amount not to exceed $20.0 billio
Is ABT overvalued? See what's priced in →
3,016 institutional managers reported holding ABT in 13F filings for the quarter ended 2026-03-31. Together they hold about 77% of the company; the top 10 hold 38%. 138 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 22.0M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (1.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ABT has cut its share count 2.1% over the past five years, spending $8.94B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 12 years straight; the current rate is $2.40 a share annually. Cash returned over the past three years: $10.83B in dividends and $2.63B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ABT over the trailing three years: 2026: 4 buys totaling $3.28M. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ABT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +6.5% | -10.0% |
| 2023-11-02 | +3.6% | +15.7% |
| 2024-02-17 | +1.3% | -5.9% |
| 2024-05-03 | -0.1% | -1.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ABT's latest 8-K filings: 2026-08-20 (items 7.01, 8.01, 9.01); 2026-07-16 (items 2.02, 9.01); 2026-04-27 (items 5.02, 5.03, 5.07, 9.01); 2026-04-17 (items 8.01, 9.01); 2026-04-16 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.